Workflow
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
LYRALyra Therapeutics(LYRA) ZACKS·2025-05-06 22:20

Company Performance - Lyra Therapeutics reported a quarterly loss of 0.12pershare,betterthantheZacksConsensusEstimateofalossof0.12 per share, better than the Zacks Consensus Estimate of a loss of 0.15, and an improvement from a loss of 0.35pershareayearago,representinganearningssurpriseof200.35 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of 0.18 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 23.75%, and a decline from year-ago revenues of 0.53million[2]−Overthelastfourquarters,thecompanyhassurpassedconsensusEPSestimatesthreetimes,buthastoppedconsensusrevenueestimatesonlyonce[2]StockPerformance−LyraTherapeuticsshareshavedeclinedapproximately49.70.53 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times, but has topped consensus revenue estimates only once [2] Stock Performance - Lyra Therapeutics shares have declined approximately 49.7% since the beginning of the year, compared to a decline of 3.9% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -0.17 on revenues of 0.24million,andforthecurrentfiscalyear,itis−0.24 million, and for the current fiscal year, it is -0.61 on revenues of $0.97 million [7] Industry Outlook - The Medical - Drugs industry, to which Lyra Therapeutics belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Lyra Therapeutics may be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]